This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Petersen RC et al. (2001) Current concepts in mild cognitive impairment. Arch Neurol 58: 1985–1992
Cummings JL (2004) Alzheimer's Disease. New Engl J Med 351: 56–67
Lockhart A (2006) Imaging Alzheimer's disease pathology: one target, many ligands. Drug Discov Today 11: 1093–1099
Kantarci K and Jack CR Jr (2003) Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin N Am 13: 197–209
Engler H et al. (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129: 2856–2866
Acknowledgements
The synopsis was written by Jim Casey, Editorial Assistant, Nature Clinical Practice.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Paul M Matthews is employed by GlaxoSmithKline, which is developing therapies for Alzheimer's disease that should have applications in people with mild cognitive impairment. GlaxoSmithKline is closely collaborating with Siemens in aspects of molecular imaging.
Rights and permissions
About this article
Cite this article
Matthews, P. Molecular imaging of brain amyloid in mild cognitive impairment and Alzheimer's disease. Nat Rev Neurol 3, 366–367 (2007). https://doi.org/10.1038/ncpneuro0520
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpneuro0520